GZMA and inflammatory bowel disease: Moreover, pimecrolimus reduced the ConA‐induced release of granzyme A and TRAIL in both tissues from IBD (granzyme A: 6‐fold, TRAIL: 2.6‐fold) and non‐IBD (granzyme A: 14‐fold, TRAIL: 6‐fold) patients (Figure 3L,N), whereas granzyme B secretion remained unaltered in both groups (Figure 3M).